Inovio Pharmaceuticals (NASDAQ:INO) Buy Rating Reaffirmed Today By H.C. Wainwright; The PT is Set to $13.0

December 7, 2017 - By Vivian Park

 Inovio Pharmaceuticals (NASDAQ:INO) Buy Rating Reaffirmed Today By H.C. Wainwright; The PT is Set to $13.0

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

Recently, In a research note sent to clients and investors on Friday morning, Inovio Pharmaceuticals (NASDAQ:INO) shares have had their Buy Rating maintained by research analysts at H.C. Wainwright, who currently has a $13.0 target price on firm. This target by H.C. Wainwright gives the possibile upside of 196.80 % from the last stock close.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. Maxim Group downgraded the shares of INO in report on Tuesday, August 9 to “Hold” rating. As per Thursday, October 5, the company rating was maintained by Stifel Nicolaus. PiperJaffray upgraded Inovio Pharmaceuticals, Inc. (NASDAQ:INO) on Thursday, June 8 to “Overweight” rating. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, June 8. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Buy” rating by Aegis Capital on Thursday, June 8. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has “Buy” rating given on Thursday, June 1 by Maxim Group. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has “Buy” rating given on Wednesday, August 9 by Maxim Group. The company was maintained on Wednesday, September 9 by Maxim Group. H.C. Wainwright maintained it with “Buy” rating and $13.0 target in Tuesday, October 17 report. The firm has “Buy” rating by Citigroup given on Wednesday, September 6.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 EPS, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual EPS reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Globenewswire.com which released: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” on December 06, 2017. Also Globenewswire.com published the news titled: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” on November 27, 2017. Fool.com‘s news article titled: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” with publication date: November 09, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.